142 related articles for article (PubMed ID: 28259362)
1. A systematic review of methods for quantifying serum testosterone in patients with prostate cancer who underwent castration.
Comas I; Ferrer R; Planas J; Celma A; Regis L; Morote J
Actas Urol Esp (Engl Ed); 2018 Mar; 42(2):86-93. PubMed ID: 28259362
[TBL] [Abstract][Full Text] [Related]
2. Measurement of serum testosterone during androgenic suppression in patients with prostate cancer: A systematic review.
Morote J; Regis L; Celma A; Planas J
Actas Urol Esp; 2016 Oct; 40(8):477-84. PubMed ID: 26899928
[TBL] [Abstract][Full Text] [Related]
3. Accuracy of serum luteinizing hormone and serum testosterone measurements to assess the efficacy of medical castration in prostate cancer patients.
Morote J; Comas I; Ferrer R; Planas J; Celma A; Regis L
J Biomed Sci; 2017 Oct; 24(1):81. PubMed ID: 29058606
[TBL] [Abstract][Full Text] [Related]
4. Serum Testosterone Levels in Prostate Cancer Patients Undergoing Luteinizing Hormone-Releasing Hormone Agonist Therapy.
Morote J; Comas I; Planas J; Maldonado X; Celma A; Placer J; Ferrer R; Carles J; Regis L
Clin Genitourin Cancer; 2018 Apr; 16(2):e491-e496. PubMed ID: 29198640
[TBL] [Abstract][Full Text] [Related]
5. Lower testosterone levels with luteinizing hormone-releasing hormone agonist therapy than with surgical castration: new insights attained by mass spectrometry.
van der Sluis TM; Bui HN; Meuleman EJ; Heijboer AC; Hartman JF; van Adrichem N; Boevé E; de Ronde W; van Moorselaar RJ; Vis AN
J Urol; 2012 May; 187(5):1601-6. PubMed ID: 22425112
[TBL] [Abstract][Full Text] [Related]
6. Methods for Evaluating the Efficacy of Medical Castration: A Systematic Review.
Aguilar A; Planas J; Trilla E; Morote J
Cancers (Basel); 2023 Jul; 15(13):. PubMed ID: 37444589
[TBL] [Abstract][Full Text] [Related]
7. Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making.
Oefelein MG; Feng A; Scolieri MJ; Ricchiutti D; Resnick MI
Urology; 2000 Dec; 56(6):1021-4. PubMed ID: 11113751
[TBL] [Abstract][Full Text] [Related]
8. Testosterone analysis in castrated prostate cancer patients: suitability of the castration cut-off and analytical accuracy of the present-day clinical immunoassays.
van Winden LJ; Lentjes EGWM; Demir AY; Huijgen HJ; Bergman AM; van der Poel HG; van Rossum HH
Clin Chem Lab Med; 2022 Sep; 60(10):1661-1668. PubMed ID: 35918785
[TBL] [Abstract][Full Text] [Related]
9. Serum testosterone levels after medical or surgical androgen deprivation: a comprehensive review of the literature.
Nishiyama T
Urol Oncol; 2014 Jan; 32(1):38.e17-28. PubMed ID: 23769268
[TBL] [Abstract][Full Text] [Related]
10. Serum testosterone measured by liquid chromatography-tandem mass spectrometry is an independent predictor of response to castration in metastatic hormone-sensitive prostate cancer.
van Winden LJ; Lanfermeijer M; Dezentje V; Bergman AM; van der Poel HG; van Rossum HH
Clin Chim Acta; 2023 Jan; 539():34-40. PubMed ID: 36460134
[TBL] [Abstract][Full Text] [Related]
11. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.
Morote J; Orsola A; Planas J; Trilla E; Raventós CX; Cecchini L; Catalán R
J Urol; 2007 Oct; 178(4 Pt 1):1290-5. PubMed ID: 17698136
[TBL] [Abstract][Full Text] [Related]
12. Measurement of total serum testosterone in adult men: comparison of current laboratory methods versus liquid chromatography-tandem mass spectrometry.
Wang C; Catlin DH; Demers LM; Starcevic B; Swerdloff RS
J Clin Endocrinol Metab; 2004 Feb; 89(2):534-43. PubMed ID: 14764758
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous Measurement of Serum Chemical Castration Agents and Testosterone Levels Using Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry.
Ko DH; Lee K; Jeon SH; Song SH; Yun YM; Chun S; Kim HS; Kim JY; In MK; Song J
J Anal Toxicol; 2016 May; 40(4):294-303. PubMed ID: 26989223
[TBL] [Abstract][Full Text] [Related]
14. High serum dihydrotestosterone examined by ultrasensitive LC-MS/MS as a predictor of benign prostatic hyperplasia or Gleason score 6 cancer in men with prostate-specific antigen levels of 3-10 ng/mL.
Miyoshi Y; Uemura H; Suzuki K; Shibata Y; Honma S; Harada M; Kubota Y
Andrology; 2017 Mar; 5(2):262-267. PubMed ID: 27813361
[TBL] [Abstract][Full Text] [Related]
15. Androgen and prostatic stroma.
Niu YJ; Ma TX; Zhang J; Xu Y; Han RF; Sun G
Asian J Androl; 2003 Mar; 5(1):19-26. PubMed ID: 12646998
[TBL] [Abstract][Full Text] [Related]
16. Validation of a high throughput method for serum/plasma testosterone using liquid chromatography tandem mass spectrometry (LC-MS/MS).
Singh RJ
Steroids; 2008 Dec; 73(13):1339-44. PubMed ID: 18703076
[TBL] [Abstract][Full Text] [Related]
17. Free Testosterone During Androgen Deprivation Therapy Predicts Castration-Resistant Progression Better Than Total Testosterone.
Regis L; Planas J; Carles J; Maldonado X; Comas I; Ferrer R; Morote J
Prostate; 2017 Jan; 77(1):114-120. PubMed ID: 27800640
[TBL] [Abstract][Full Text] [Related]
18. Luteinizing Hormone-Releasing Hormone Agonists are Superior to Subcapsular Orchiectomy in Lowering Testosterone Levels of Men with Prostate Cancer: Results from a Randomized Clinical Trial.
Østergren PB; Kistorp C; Fode M; Henderson J; Bennedbæk FN; Faber J; Sønksen J
J Urol; 2017 Jun; 197(6):1441-1447. PubMed ID: 27939836
[TBL] [Abstract][Full Text] [Related]
19. [Time-course of plasma testosterone in patients with prostate cancer treated by endocrine therapy].
Peyromaure M; Rebillard X; Ruffion A; Salomon L; Villers A; Soulie M;
Prog Urol; 2008 Jan; 18(1):2-8. PubMed ID: 18342148
[TBL] [Abstract][Full Text] [Related]
20. [Hormone release and intermittent hormonal therapy in the LN CaP model of human prostate cancer].
Gleave M; Santo N; Rennie PS; Goldenberg SL; Bruchovsky N; Sullivan LD
Prog Urol; 1996 Jun; 6(3):375-85. PubMed ID: 8763692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
